Stago Group Acquires HemoSonics
By Labmedica International staff writers
Posted on 30 May 2017
Image: The Stago Group has acquired HemoSonics as part of ongoing efforts to diversify its portfolio of medical devices (Photo courtesy of iStock).
The Stago Group, which develops and markets automated systems for blood analysis in coagulation, has completed the acquisition of HemoSonics LLC, a developer of point-of-care (POC) testing solutions.
Stago, a leading player in the in-vitro diagnostics industry, focuses on the exploration of thrombosis and hemostasis. HemoSonics, a medical device company, develops POC diagnostic platforms to guide the management of critical bleeding in order to improve outcomes and enable more targeted transfusion of blood products.
Stago’s acquisition of HemoSonics is a part of the company's on-going efforts to diversify its portfolio of medical devices. With the acquisition of HemoSonics’ patented SEER technology (Sonic Estimation of Elasticity via Resonance) and its associated Quantra hemostasis analyzer, Stago expects to further strengthen its position in the hemostasis testing market.
“This significant step makes us very proud to contribute to the management of healthcare costs and to the improvement of patients outcomes worldwide,” said Lionel Viret, Chairman of the Board, Stago Group.
“Stago brings exceptional expertise in the field of thrombosis and hemostasis that will greatly advance our efforts to rapidly and effectively deliver a new standard of care for the management of bleeding in the critical care setting,” said Timothy Fischer, President and Chief Executive Officer of HemoSonics.